Targeting AMPK for cardiac protection: Opportunities and challenges

Journal of Molecular and Cellular Cardiology

Volumn 51, Issue 4, 2011, Pages 548-553

  Kim, Maengjo ^a   Tian, Rong ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

AMPK; Cardiomyopathy; Drug target; Energy homeostasis; Isoform

Indexed keywords

6,7 DIHYDRO 4 HYDROXY 3 (2' HYDROXY 1,1' BIPHENYL 4 YL) 6 OXOTHIENO[2,3 B]PYRIDINE 5 CARBONITRILE; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE BETA; GLYCOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PROTEIN KINASE LKB1; PROTEIN SUBUNIT; UNCLASSIFIED DRUG;

CARBOXY TERMINAL SEQUENCE; CELL DEATH; CELL SURVIVAL; ENZYME ACTIVATION; ENZYME INHIBITION; HEART MUSCLE CELL; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; INTRACELLULAR SIGNALING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REPERFUSION INJURY; REVIEW; TISSUE DISTRIBUTION;

ADENYLATE KINASE; ANIMALS; CARDIOVASCULAR DISEASES; ENZYME ACTIVATORS; GENE EXPRESSION; HUMANS; ISOENZYMES; MOLECULAR TARGETED THERAPY; MUTATION; MYOCARDIUM; ORGAN SPECIFICITY; PROTEIN SUBUNITS; STRESS, PHYSIOLOGICAL;

EID: 79961039309     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2010.12.004     Document Type: Review

References (91)

1. Kemp B.E., Stapleton D., Campbell D.J., Chen Z.P., Murthy S., Walter M., et al. AMP-activated protein kinase, super metabolic regulator. Biochem Soc Trans Feb 2003, 31(Pt 1):162-168.
2. Carling D. The AMP-activated protein kinase cascade - a unifying system for energy control. Trends Biochem Sci Jan 2004, 29(1):18-24.
3. Hardie D.G. AMPK and raptor: matching cell growth to energy supply. Mol Cell May 9 2008, 30(3):263-265.
4. Luo Z., Zang M., Guo W. AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol. Mar 2010, 6(3):457-470.
5. Jager S., Handschin C., St-Pierre J., Spiegelman B.M. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci USA Jul 17 2007, 104(29):12017-12022.
6. Towler M.C., Hardie D.G. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res Feb 16 2007, 100(3):328-341.
7. Warden S.M., Richardson C., O'Donnell J., Stapleton D., Kemp B.E., Witters L.A. Post-translational modifications of the beta-1 subunit of AMP-activated protein kinase affect enzyme activity and cellular localization. Biochem J Mar 1 2001, 354(Pt 2):275-283.
8. Scott J.W., Hawley S.A., Green K.A., Anis M., Stewart G., Scullion G.A., et al. CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations. J Clin Invest Jan 2004, 113(2):274-284.
9. Xiao B., Heath R., Saiu P., Leiper F.C., Leone P., Jing C., et al. Structural basis for AMP binding to mammalian AMP-activated protein kinase. Nature Sep 27 2007, 449(7161):496-500.
10. Davies S.P., Helps N.R., Cohen P.T., Hardie D.G. 5'-AMP inhibits dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2C alpha and native bovine protein phosphatase-2AC. FEBS Lett Dec 27 1995, 377(3):421-425.
11. Suter M., Riek U., Tuerk R., Schlattner U., Wallimann T., Neumann D. Dissecting the role of 5'-AMP for allosteric stimulation, activation, and deactivation of AMP-activated protein kinase. J Biol Chem Oct 27 2006, 281(43):32207-32216.
12. Hardie D.G., Salt I.P., Hawley S.A., Davies S.P. AMP-activated protein kinase: an ultrasensitive system for monitoring cellular energy charge. Biochem J Mar 15 1999, 338(Pt 3):717-722.
13. Sakamoto K., Goransson O., Hardie D.G., Alessi D.R. Activity of LKB1 and AMPK-related kinases in skeletal muscle: effects of contraction, phenformin, and AICAR. Am J Physiol Endocrinol Metab Aug 2004, 287(2):E310-E317.
14. Hawley S.A., Boudeau J., Reid J.L., Mustard K.J., Udd L., Makela T.P., et al. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2003, 2(4):28.
15. Anderson K.A., Ribar T.J., Lin F., Noeldner P.K., Green M.F., Muehlbauer M.J., et al. Hypothalamic CaMKK2 contributes to the regulation of energy balance. Cell Metab May 2008, 7(5):377-388.
16. Lee J.Y., Jeon B.T., Shin H.J., Lee D.H., Han J.Y., Kim H.J., et al. Temporal expression of AMP-activated protein kinase activation during the kainic acid-induced hippocampal cell death. J Neural Transm Jan 2009, 116(1):33-40.
17. Momcilovic M., Hong S.P., Carlson M. Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro. J Biol Chem Sep 1 2006, 281(35):25336-25343.
18. Herrero-Martin G., Hoyer-Hansen M., Garcia-Garcia C., Fumarola C., Farkas T., Lopez-Rivas A., et al. TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells. EMBO J Mar 18 2009, 28(6):677-685.
19. Xie M., Zhang D., Dyck J.R., Li Y., Zhang H., Morishima M., et al. A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. Proc Natl Acad Sci USA Nov 14 2006, 103(46):17378-17383.
20. Shibata R., Sato K., Pimentel D.R., Takemura Y., Kihara S., Ohashi K., et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med Oct 2005, 11(10):1096-1103.
21. Minokoshi Y., Kim Y.B., Peroni O.D., Fryer L.G., Muller C., Carling D., et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature Jan 17 2002, 415(6869):339-343.
22. Steinberg G.R., Watt M.J., Fam B.C., Proietto J., Andrikopoulos S., Allen A.M., et al. Ciliary neurotrophic factor suppresses hypothalamic AMP-kinase signaling in leptin-resistant obese mice. Endocrinology Aug 2006, 147(8):3906-3914.
23. Andersson U., Filipsson K., Abbott C.R., Woods A., Smith K., Bloom S.R., et al. AMP-activated protein kinase plays a role in the control of food intake. J Biol Chem Mar 26 2004, 279(13):12005-12008.
24. Stapleton D., Mitchelhill K.I., Gao G., Widmer J., Michell B.J., Teh T., et al. Mammalian AMP-activated protein kinase subfamily. J Biol Chem Jan 12 1996, 271(2):611-614.
25. Thornton C., Snowden M.A., Carling D. Identification of a novel AMP-activated protein kinase beta subunit isoform that is highly expressed in skeletal muscle. J Biol Chem May 15 1998, 273(20):12443-12450.
26. Cheung P.C., Salt I.P., Davies S.P., Hardie D.G., Carling D. Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding. Biochem J Mar 15 2000, 346(Pt 3):659-669.
27. Yang Z., Kahn B.B., Shi H., Xue B.Z. Macrophage alpha1 AMP-activated protein kinase (alpha1AMPK) antagonizes fatty acid-induced inflammation through SIRT1. J Biol Chem. Jun 18 2010, 285(25):19051-19059.
28. Wojtaszewski J.F., Birk J.B., Frosig C., Holten M., Pilegaard H., Dela F. 5'AMP activated protein kinase expression in human skeletal muscle: effects of strength training and type 2 diabetes. J Physiol Apr 15 2005, 564(Pt 2):563-573.
29. Treebak J.T., Birk J.B., Rose A.J., Kiens B., Richter E.A., Wojtaszewski J.F. AS160 phosphorylation is associated with activation of alpha2beta2gamma1 - but not alpha2beta2gamma3-AMPK trimeric complex in skeletal muscle during exercise in humans. Am J Physiol Endocrinol Metab Mar 2007, 292(3):E715-E722.
30. Birk J.B., Wojtaszewski J.F. Predominant alpha2/beta2/gamma3 AMPK activation during exercise in human skeletal muscle. J Physiol Dec 15 2006, 577(Pt 3):1021-1032.
31. McGee S.L., Howlett K.F., Starkie R.L., Cameron-Smith D., Kemp B.E., Hargreaves M. Exercise increases nuclear AMPK alpha2 in human skeletal muscle. Diabetes Apr 2003, 52(4):926-928.
32. McGee S.L., Fairlie E., Garnham A.P., Hargreaves M. Exercise-induced histone modifications in human skeletal muscle. J Physiol Dec 15 2009, 587(Pt 24):5951-5958.
33. Suzuki A., Okamoto S., Lee S., Saito K., Shiuchi T., Minokoshi Y. Leptin stimulates fatty acid oxidation and peroxisome proliferator-activated receptor alpha gene expression in mouse C2C12 myoblasts by changing the subcellular localization of the alpha2 form of AMP-activated protein kinase. Mol Cell Biol 2007 Jun, 27(12):4317-4327.
34. Li J., Coven D.L., Miller E.J., Hu X., Young M.E., Carling D., et al. Activation of AMPK alpha- and gamma-isoform complexes in the intact ischemic rat heart. Am J Physiol Heart Circ Physiol Oct 2006, 291(4):H1927-H1934.
35. Musi N., Hirshman M.F., Arad M., Xing Y., Fujii N., Pomerleau J., et al. Functional role of AMP-activated protein kinase in the heart during exercise. FEBS Lett Apr 11 2005, 579(10):2045-2050.
36. Tian R., Musi N., D'Agostino J., Hirshman M.F., Goodyear L.J. Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy. Circulation Oct 2 2001, 104(14):1664-1669.
37. Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest Oct 2001, 108(8):1167-1174.
38. Marsin A.S., Bertrand L., Rider M.H., Deprez J., Beauloye C., Vincent M.F., et al. Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr Biol Oct 19 2000, 10(20):1247-1255.
39. Russell R.R., Bergeron R., Shulman G.I., Young L.H. Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. Am J Physiol Aug 1999, 277(2 Pt 2):H643-H649.
40. Russell R.R., Li J., Coven D.L., Pypaert M., Zechner C., Palmeri M., et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest Aug 2004, 114(4):495-503.
41. Xing Y., Musi N., Fujii N., Zou L., Luptak I., Hirshman M.F., et al. Glucose metabolism and energy homeostasis in mouse hearts overexpressing dominant negative alpha2 subunit of AMP-activated protein kinase. J Biol Chem Aug 1 2003, 278(31):28372-28377.
42. Dyck J.R., Kudo N., Barr A.J., Davies S.P., Hardie D.G., Lopaschuk G.D. Phosphorylation control of cardiac acetyl-CoA carboxylase by cAMP-dependent protein kinase and 5'-AMP activated protein kinase. Eur J Biochem May 1999, 262(1):184-190.
43. Lopaschuk G.D., Spafford M.A. Energy substrate utilization by isolated working hearts from newborn rabbits. Am J Physiol May 1990, 258(5 Pt 2):H1274-H1280.
44. Hendrickson S.C., St Louis J.D., Lowe J.E. Abdel aleem S Free fatty acid metabolism during myocardial ischemia reperfusion. Mol Cell Biochem Jan 1997, 166(1-2):85-94.
45. Inoki K., Ouyang H., Zhu T., Lindvall C., Wang Y., Zhang X., et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell Sep 8 2006, 126(5):955-968.
46. Li H.L., Yin R., Chen D., Liu D., Wang D., Yang Q., et al. Long-term activation of adenosine monophosphate-activated protein kinase attenuates pressure-overload-induced cardiac hypertrophy. J Cell Biochem Apr 1 2007, 100(5):1086-1099.
47. Chan A.Y., Soltys C.L., Young M.E., Proud C.G., Dyck J.R. Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. J Biol Chem Jul 30 2004, 279(31):32771-32779.
48. Chen B.L., Ma Y.D., Meng R.S., Xiong Z.J., Wang H.N., Zeng J.Y., et al. Activation of AMPK inhibits cardiomyocyte hypertrophy by modulating of the FOXO1/MuRF1 signaling pathway in vitro. Acta Pharmacol Sin. Jul 2010, 31(7):798-804.
49. Dolinsky V.W., Morton J.S., Oka T., Robillard-Frayne I., Bagdan M., Lopaschuk G.D., et al. Calorie restriction prevents hypertension and cardiac hypertrophy in the spontaneously hypertensive rat. Hypertension Aug 9 2010, 9.
50. Gundewar S., Calvert J.W., Jha S., Toedt-Pingel I., Ji S.Y., Nunez D., et al. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res Feb 13 2009, 104(3):403-411.
51. Longnus S.L., Wambolt R.B., Parsons H.L., Brownsey R.W., Allard M.F. 5-Aminoimidazole-4-carboxamide 1-beta -D-ribofuranoside (AICAR) stimulates myocardial glycogenolysis by allosteric mechanisms. Am J Physiol Regul Integr Comp Physiol Apr 2003, 284(4):R936-R944.
52. Vincent M.F., Marangos P.J., Gruber H.E., Van den Berghe G. Inhibition by AICA riboside of gluconeogenesis in isolated rat hepatocytes. Diabetes Oct 1991, 40(10):1259-1266.
53. Musi N., Goodyear L.J. Targeting the AMP-activated protein kinase for the treatment of type 2 diabetes. Curr Drug Targets Immune Endocr Metab Disord Jul 2002, 2(2):119-127.
54. Dargie H.J., Hildebrandt P.R., Riegger G.A., McMurray J.J., McMorn S.O., Roberts J.N., et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. J Am Coll Cardiol Apr 24 2007, 49(16):1696-1704.
55. Foretz M., Hebrard S., Leclerc J., Zarrinpashneh E., Soty M., Mithieux G., et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest. Jul 1 2010, 120(7):2355-2369.
56. Kalender A., Selvaraj A., Kim S.Y., Gulati P., Brule S., Viollet B., et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. May 5 2010, 11(5):390-401.
57. Dyck J.R., Gao G., Widmer J., Stapleton D., Fernandez C.S., Kemp B.E., et al. Regulation of 5'-AMP-activated protein kinase activity by the noncatalytic beta and gamma subunits. J Biol Chem Jul 26 1996, 271(30):17798-17803.
58. Crute B.E., Seefeld K., Gamble J., Kemp B.E., Witters L.A. Functional domains of the alpha1 catalytic subunit of the AMP-activated protein kinase. J Biol Chem Dec 25 1998, 273(52):35347-35354.
59. Zou L., Shen M., Arad M., He H., Lofgren B., Ingwall J.S., et al. N488I mutation of the gamma2-subunit results in bidirectional changes in AMP-activated protein kinase activity. Circ Res Aug 19 2005, 97(4):323-328.
60. Barnes B.R., Marklund S., Steiler T.L., Walter M., Hjalm G., Amarger V., et al. The 5'-AMP-activated protein kinase gamma3 isoform has a key role in carbohydrate and lipid metabolism in glycolytic skeletal muscle. J Biol Chem Sep 10 2004, 279(37):38441-38447.
61. Milan D., Jeon J.T., Looft C., Amarger V., Robic A., Thelander M., et al. A mutation in PRKAG3 associated with excess glycogen content in pig skeletal muscle. Science May 19 2000, 288(5469):1248-1251.
62. Costford S.R., Kavaslar N., Ahituv N., Chaudhry S.N., Schackwitz W.S., Dent R., et al. Gain-of-function R225W mutation in human AMPKgamma(3) causing increased glycogen and decreased triglyceride in skeletal muscle. PLoS ONE 2007, 2(9):e903.
63. Arad M., Benson D.W., Perez-Atayde A.R., McKenna W.J., Sparks E.A., Kanter R.J., et al. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest Feb 2002, 109(3):357-362.
64. Gollob M.H., Seger J.J., Gollob T.N., Tapscott T., Gonzales O., Bachinski L., et al. Novel PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitation and conduction system disease with childhood onset and absence of cardiac hypertrophy. Circulation Dec 18 2001, 104(25):3030-3033.
65. Blair E., Redwood C., Ashrafian H., Oliveira M., Broxholme J., Kerr B., et al. Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet May 15 2001, 10(11):1215-1220.
66. Ahmad F., Arad M., Musi N., He H., Wolf C., Branco D., et al. Increased alpha2 subunit-associated AMPK activity and PRKAG2 cardiomyopathy. Circulation Nov 15 2005, 112(20):3140-3148.
67. Luptak I., Shen M., He H., Hirshman M.F., Musi N., Goodyear L.J., et al. Aberrant activation of AMP-activated protein kinase remodels metabolic network in favor of cardiac glycogen storage. J Clin Invest May 2007, 117(5):1432-1439.
68. Folmes K.D., Chan A.Y., Koonen D.P., Pulinilkunnil T.C., Baczko I., Hunter B.E., et al. Distinct early signaling events resulting from the expression of the PRKAG2 R302Q mutant of AMPK contribute to increased myocardial glycogen. Circ Cardiovasc Genet Oct 2009, 2(5):457-466.
69. Davies J.K., Wells D.J., Liu K., Whitrow H.R., Daniel T.D., Grignani R., et al. Characterization of the role of gamma2 R531G mutation in AMP-activated protein kinase in cardiac hypertrophy and Wolff-Parkinson-White syndrome. Am J Physiol Heart Circ Physiol May 2006, 290(5):H1942-H1951.
70. Sun W., Lee T.S., Zhu M., Gu C., Wang Y., Zhu Y., et al. Statins activate AMP-activated protein kinase in vitro and in vivo. Circulation Dec 12 2006, 114(24):2655-2662.
71. Stahmann N., Woods A., Spengler K., Heslegrave A., Bauer R., Krause S., et al. Activation of AMP-activated protein kinase by vascular endothelial growth factor mediates endothelial angiogenesis independently of nitric-oxide synthase. J Biol Chem. Apr 2 2010, 285(14):10638-10652.
72. Dixit M., Bess E., Fisslthaler B., Hartel F.V., Noll T., Busse R., et al. Shear stress-induced activation of the AMP-activated protein kinase regulates FoxO1a and angiopoietin-2 in endothelial cells. Cardiovasc Res Jan 2008, 77(1):160-168.
73. Zhang Y., Lee T.S., Kolb E.M., Sun K., Lu X., Sladek F.M., et al. AMP-activated protein kinase is involved in endothelial NO synthase activation in response to shear stress. Arterioscler Thromb Vasc Biol Jun 2006, 26(6):1281-1287.
74. Chen Z.P., Mitchelhill K.I., Michell B.J., Stapleton D., Rodriguez-Crespo I., Witters L.A., et al. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett Jan 29 1999, 443(3):285-289.
75. Nagata D., Takeda R., Sata M., Satonaka H., Suzuki E., Nagano T., et al. AMP-activated protein kinase inhibits angiotensin II-stimulated vascular smooth muscle cell proliferation. Circulation Jul 27 2004, 110(4):444-451.
76. Du J.H., Xu N., Song Y., Xu M., Lu Z.Z., Han C., et al. AICAR stimulates IL-6 production via p38 MAPK in cardiac fibroblasts in adult mice: a possible role for AMPK. Biochem Biophys Res Commun Dec 2 2005, 337(4):1139-1144.
77. Jorgensen S.B., Viollet B., Andreelli F., Frosig C., Birk J.B., Schjerling P., et al. Knockout of the alpha2 but not alpha1 5'-AMP-activated protein kinase isoform abolishes 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranosidebut not contraction-induced glucose uptake in skeletal muscle. J Biol Chem Jan 9 2004, 279(2):1070-1079.
78. Viollet B., Andreelli F., Jorgensen S.B., Perrin C., Flamez D., Mu J., et al. Physiological role of AMP-activated protein kinase (AMPK): insights from knockout mouse models. Biochem Soc Trans Feb 2003, 31(Pt 1):216-219.
79. Quinn J.M., Tam S., Sims N.A., Saleh H., McGregor N.E., Poulton I.J., et al. Germline deletion of AMP-activated protein kinase beta subunits reduces bone mass without altering osteoclast differentiation or function. FASEB J Jan 2009, 24(1):275-285.
80. Zhang P., Hu X., Xu X., Fassett J., Zhu G., Viollet B., et al. AMP activated protein kinase-alpha2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice. Hypertension Nov 2008, 52(5):918-924.
81. Zarrinpashneh E., Carjaval K., Beauloye C., Ginion A., Mateo P., Pouleur A.C., et al. Role of the alpha2-isoform of AMP-activated protein kinase in the metabolic response of the heart to no-flow ischemia. Am J Physiol Heart Circ Physiol Dec 2006, 291(6):H2875-H2883.
82. Folmes C.D., Wagg C.S., Shen M., Clanachan A.S., Tian R., Lopaschuk G.D. Suppression of 5'-AMP-activated protein kinase activity does not impair recovery of contractile function during reperfusion of ischemic hearts. Am J Physiol Heart Circ Physiol Jul 2009, 297(1):H313-H321.
83. Bain J., Plater L., Elliott M., Shpiro N., Hastie C.J., McLauchlan H., et al. The selectivity of protein kinase inhibitors: a further update. Biochem J Dec 15 2007, 408(3):297-315.
84. Emerling B.M., Viollet B., Tormos K.V., Chandel N.S. Compound C inhibits hypoxic activation of HIF-1 independent of AMPK. FEBS Lett Dec 11 2007, 581(29):5727-5731.
85. Hawley S.A., Ross F.A., Chevtzoff C., Green K.A., Evans A., Fogarty S., et al. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab. Jun 9 2010, 11(6):554-565.
86. Scott J.W., van Denderen B.J., Jorgensen S.B., Honeyman J.E., Steinberg G.R., Oakhill J.S., et al. Thienopyridone drugs are selective activators of AMP-activated protein kinase beta1-containing complexes. Chem Biol Nov 24 2008, 15(11):1220-1230.
87. Moreno D., Knecht E., Viollet B., Sanz P. A769662, a novel activator of AMP-activated protein kinase, inhibits non-proteolytic components of the 26S proteasome by an AMPK-independent mechanism. FEBS Lett Jul 23 2008, 582(17):2650-2654.
88. Pang T., Zhang Z.S., Gu M., Qiu B.Y., Yu L.F., Cao P.R., et al. Small molecule antagonizes autoinhibition and activates AMP-activated protein kinase in cells. J Biol Chem Jun 6 2008, 283(23):16051-16060.
89. Minokoshi Y., Alquier T., Furukawa N., Kim Y.B., Lee A., Xue B., et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature Apr 1 2004, 428(6982):569-574.
90. Olson D.P., Pulinilkunnil T., Cline G.W., Shulman G.I., Lowell B.B. Gene knockout of Acc2 has little effect on body weight, fat mass, or food intake. Proc Natl Acad Sci U S A. Apr 20 2010, 107(6):7598-7603.
91. Hoehn K.L., Turner N., Swarbrick M.M., Wilks D., Preston E., Phua Y., et al. Acute or chronic upregulation of mitochondrial fatty acid oxidation has no net effect on whole-body energy expenditure or adiposity. Cell Metab. Jan 2010, 11(1):70-76.